Novel small molecule bradykinin B1 receptor antagonists. Part 2: 5-membered diaminoheterocycles

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 3, 2010, Pages 1229-1232

  Zischinsky, Gunther ^a   Stragies, Roland ^a   Schaudt, Marco ^a   Pfeifer, Jochen R ^a   Gibson, Christoph ^a   Locardi, Elsa ^a   Scharn, Dirk ^a   Richter, Uwe ^a   Kalkhof, Holger ^a   Dinkel, Klaus ^a   Schnatbaum, Karsten ^a  

^a Jerini AG   (Germany)

Author keywords

Antagonist; Oral bioavailability; Pharmacokinetic profile

Indexed keywords

2 AMINOBENZIMIDAZOLE; BRADYKININ B1 RECEPTOR ANTAGONIST; DIAMINOHETEROCYCLE; HETEROCYCLIC COMPOUND; UNCLASSIFIED DRUG; 2-AMINOBENZIMIDAZOLE; BENZIMIDAZOLE DERIVATIVE; BRADYKININ B1 RECEPTOR; DIAMINE;

ARTICLE; CELL STRAIN CACO 2; DRUG SYNTHESIS; HUMAN; HUMAN CELL; STRUCTURE ACTIVITY RELATION; CELL LINE; CHEMISTRY; COMPARATIVE STUDY; DRUG EFFECTS; FIBROBLAST; METABOLISM;

BENZIMIDAZOLES; BRADYKININ B1 RECEPTOR ANTAGONISTS; CELL LINE; DIAMINES; FIBROBLASTS; HETEROCYCLIC COMPOUNDS; HUMANS; RECEPTOR, BRADYKININ B1; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 74049108918     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.11.120     Document Type: Article

References (26)

1. Bhoola K.D., Figueroa C.D., and Worthy K. Pharmacol. Rev. 44 (1992) 1
2. Leeb-Lundberg L.M.F., Marceau F., Mueller-Esterl W., Pettibone D.J., and Zuraw B.L. Pharmacol. Rev. 90 (2005) 8234
3. Marceau F., Hess J.F., and Bachvarov D.R. Pharmacol. Rev. 50 (1998) 357
4. Ahluwalia A., and Perretti M. J. Immunol. 156 (1996) 269
5. Calixto J.B., Medeiros R., Fernandes E.S., Ferreira J., Cabrini D.A., and Campos M.M. Br. J. Pharmacol. 348 (2004) 803
6. Ehrenfeld P., Millan C., Matus C., Figueroa J.E., Burgos R.A., Nualart F., Bhoola K., and Figueroa C.D. J. Leukocyte Biol. 80 (2006) 117
7. Paegelow I., Trzeczak S., Böckmann S., and Vietinghoff G. Pharmacology 66 (2002) 153
8. Chen J.J., and Biswas K. Prog. Med. Chem. 46 (2008) 173
9. Duchene J., and Ahluwalia A. Curr. Opin. Pharmacol. 9 (2009) 125
10. Cassim B., Shaw O.M., Mazur M., Misso N.L., Naran A., Langlands D.R., Thompson P.J., and Bhoola K.D. Rheumatology 48 (2009) 490
11. Stadnicki A., Pastucha E., Nowaczyk G., Mazurek U., Plewka D., Machnik G., Wilczok T., and Colman R.W. Am. J. Physiol. Gastrointest. Liver Physiol. 289 (2005) G361
12. Pietrovski E.F., Otuki M.F., Regoli D., Bader M., Pesquero J.B., Cabrini D.A., and Zampronio A.R. Regul. Pept. 152 (2009) 67
13. Marceau F., and Regoli D. Nat. Rev. Drug Disc. 3 (2004) 845
14. 1 receptor antagonists.
15. Bemis G.W., and Murcko M.A. J. Med. Chem. 39 (1996) 2887
16. Wood M.R., Books K.M., Kim J.J., Wan B.-L., Murphy K.L., Ransom R.W., Chang R.S.L., Tang C., Prueksaritanont T., Detwiler T.J., Hettrick L.A., Landis E.R., Leonard Y.M., Krueger J.A., Lewis S.D., Pettibone D.J., Freidinger R.M., and Bock M.G. J. Med. Chem. 49 (2006) 1231
17. Wood M.R., Schirripa K.M., Kim J.J., Kuduk S.D., Di Marco C.N., Chang R.K., Wai J.C., DiPardo R.M., Wang B.L., Cook J.L., Holahan M.A., Lemaire W., Mosser S.D., Bednar R.A., Wallace A.A., Mei Q., Yu J., Bohn D.C., Clayton F.D., Adarayan E.A., Sitko G.R., Leonard Y.M., Murphy K.L., Ransom R.W., Harrell C.M., Tang C., Prueksaritanont T., Pettibone D.J., and Bock M.G. Bioorg. Med. Chem. Lett. 18 (2008) 716
18. Kuduk S.D., Di Marco C.N., Chang R.K., Wood M.R., Kim J.J., Schirripa K.M., Murphy K.L., Ransom R.W., Tang C., Torrent M., Ha S., Prueksaritanont T., Pettibone D.J., and Bock M.G. Bioorg. Med. Chem. Lett. 16 (2006) 2791
19. Boido A., Vazzana I., and Sparatore F. Farmaco 49 (1994) 97
20. Kuduk S.D., Di Marco C.N., Chang R.K., Wood M.R., Schirripa K.M., Kim J.J., Wai J.C., DiPardo R.M., Murphy K.L., Ransom R.W., Harrell C.M., Reiss D.R., Holahan M.A., Cook J.L., Hess J.F., Sain N., Urban M.O., Tang C., Prueksaritanont T., Pettibone D.J., and Bock M.G. J. Med. Chem. 50 (2007) 272
21. Menzel K., Machrouhi F., Bodenstein M., Alorati A., Cowden C., Gibson A.W., Bishop B., Ikemoto N., Nelson T.D., Kress M.H., and Frantz D.E. Org. Process Res. Dev. 13 (2009) 519
22. Absorption systems express bidirectional permeability assay through Caco-2 cell monolayers:. Artursson P., Palma K., and Luthmanb K. Adv. Drug Delivery Rev. 46 (2001) 27
23. Sambuy Y., De Angelis I., Ranaldi G., Scarino M.L., Stammati A., and Zucco F. Cell Biol. Toxicol. 21 (2005) 1
24. Kuduk S.D., Ng C., Feng D.-M., Wai J.M.-C., Chang R.S.L., Harrell C.M., Murphy K.L., Ransom R.W., Reiss D., Ivarsson M., Mason G., Boyce S., Tang C., Prueksaritanont T., Freidinger R.M., Pettibone D.J., and Bock M.G. J. Med. Chem. 47 (2004) 6439
25. Tang C., Subramanian R., Kuo Y., Krymgold S., Lu P., Kuduk S.D., Ng C., Feng D.M., Elmore C., Soli E., Ho J., Bock M.G., Baillie T.A., and Prueksaritanont T. Chem. Res. Toxicol. 18 (2005) 934
26. Determined as described in:. Kunz W., and Gieschen H. Drug Metab. Dispos. 26 (1998) 1120 Microsomal preparations from different species were obtained from Tebu-bio, Offenbach, Germany